US Pain Management Market

ID: MRFR/MED/12040-HCR
100 Pages
Nidhi Mandole
Last Updated: April 06, 2026
United States Pain Management Market Research Report: Size, Share, Trend Analysis - Growth Outlook & Industry Forecast 2025 To 2035
US Pain Management Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)5.34%
2024 Market Size$ 17.5 Billion
2025 Market Size$ 18.43 Billion
2035 Market Size$ 31 Billion
Key Players
Johnson & Johnson
Pfizer Inc.
AbbVie Inc.
Boehringer Ingelheim
Amgen Inc.
Eli Lilly and Company
Trends
  • Rise of Non-Opioid Therapies
  • Telehealth Integration
  • Personalized Treatment Approaches
Opportunities
  • Increasing Prevalence of Chronic Pain
  • Advancements in Pain Management Technologies
  • Growing Awareness of Pain Management Options
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Pharmaceutical, BY Type of Pain (USD Billion)
      1. 4.1.1 Acute Pain
      2. 4.1.2 Chronic Pain
      3. 4.1.3 Neuropathic Pain
      4. 4.1.4 Nociceptive Pain
    2. 4.2 Pharmaceutical, BY Treatment Type (USD Billion)
      1. 4.2.1 Medication
      2. 4.2.2 Physical Therapy
      3. 4.2.3 Interventional Procedures
      4. 4.2.4 Alternative Therapies
    3. 4.3 Pharmaceutical, BY End User (USD Billion)
      1. 4.3.1 Hospitals
      2. 4.3.2 Clinics
      3. 4.3.3 Homecare Settings
      4. 4.3.4 Rehabilitation Centers
    4. 4.4 Pharmaceutical, BY Route of Administration (USD Billion)
      1. 4.4.1 Oral
      2. 4.4.2 Topical
      3. 4.4.3 Injectable
      4. 4.4.4 Transdermal
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Pharmaceutical
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Johnson & Johnson (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Pfizer Inc. (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 AbbVie Inc. (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Boehringer Ingelheim (DE)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Amgen Inc. (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Eli Lilly and Company (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Teva Pharmaceutical Industries Ltd. (IL)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Mylan N.V. (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Novartis AG (CH)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TYPE OF PAIN
    3. 6.3 US MARKET ANALYSIS BY TREATMENT TYPE
    4. 6.4 US MARKET ANALYSIS BY END USER
    5. 6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
    9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
    11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
    12. 6.12 PHARMACEUTICAL, BY TYPE OF PAIN, 2024 (% SHARE)
    13. 6.13 PHARMACEUTICAL, BY TYPE OF PAIN, 2024 TO 2035 (USD Billion)
    14. 6.14 PHARMACEUTICAL, BY TREATMENT TYPE, 2024 (% SHARE)
    15. 6.15 PHARMACEUTICAL, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion)
    16. 6.16 PHARMACEUTICAL, BY END USER, 2024 (% SHARE)
    17. 6.17 PHARMACEUTICAL, BY END USER, 2024 TO 2035 (USD Billion)
    18. 6.18 PHARMACEUTICAL, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
    19. 6.19 PHARMACEUTICAL, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE OF PAIN, 2025-2035 (USD Billion)
      2. 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      3. 7.2.3 BY END USER, 2025-2035 (USD Billion)
      4. 7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Pain Management Market Segmentation

US Pain Management Market By Type of Pain (USD Billion, 2025-2035)

  • Acute Pain
  • Chronic Pain
  • Neuropathic Pain
  • Nociceptive Pain

US Pain Management Market By Treatment Type (USD Billion, 2025-2035)

  • Medication
  • Physical Therapy
  • Interventional Procedures
  • Alternative Therapies

US Pain Management Market By End User (USD Billion, 2025-2035)

  • Hospitals
  • Clinics
  • Homecare Settings
  • Rehabilitation Centers

US Pain Management Market By Route of Administration (USD Billion, 2025-2035)

  • Oral
  • Topical
  • Injectable
  • Transdermal

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.